Genocea Biosciences Interest Expense 2011-2026 | GNCA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Genocea Biosciences

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.12 M	1.38 M	946 K	1.02 M	1.44 M	1.74 M	1.28 M	1.02 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.74 M	946 K	1.24 M

Quarterly Interest Expense Genocea Biosciences

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	231 K	-	290 K	282 K	279 K	-	377 K	365 K	259 K	-	154 K	299 K	302 K	-	266 K	241 K	201 K	-	366 K	370 K	359 K	-	438 K	430 K	431 K	-	320 K	307 K	319 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
438 K	154 K	313 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Amneal Pharmaceuticals AMRX	16.5 M	$ 12.68	2.92 %	$ 3.97 B	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Arcutis Biotherapeutics ARQT	443 K	$ 24.48	5.18 %	$ 3.11 B	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.5	9.93 %	$ 399 M	Britain
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.9	3.72 %	$ 9.38 B	Australia
BioNTech SE BNTX	14.2 M	$ 91.86	2.5 %	$ 27.2 B	Germany
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aytu BioScience AYTU	-512 K	$ 2.68	4.28 %	$ 16.8 M	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
Cabaletta Bio CABA	2 M	$ 3.05	-0.65 %	$ 306 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.1	2.31 %	$ 6.75 B	Israel
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Cerus Corporation CERS	3.02 M	$ 1.92	4.08 %	$ 366 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	-309 K	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
CTI BioPharma Corp. CTIC	13.1 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	293 K	-	-	$ 2.02 B	USA